<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140156" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cyclodiode Laser Glaucoma Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Allbon</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>University of Auckland, Greenlane Eye Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Meyer</surname>
            <given-names>Jay J.</given-names>
          </name>
          <aff>University of Auckland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Allbon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jay Meyer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140156.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cyclodiode laser has traditionally been used to treat high intraocular pressures and refractory cases of glaucoma not amenable to medical or other surgical options. The cyclodiode laser ablates the ciliary processes, reducing aqueous humor formation and lowering the intraocular pressure. The development and advancement in cyclodiode laser delivery devices have expanded treatment options for varying glaucoma subtypes. This activity reviews the background of cyclodiode laser as a treatment for glaucoma, its mechanism of action, indications, contraindications, surgical techniques available, and potential complications, and highlights the role of the interprofessional team in evaluating and managing patients undergoing this treatment.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate&#x000a0;the available cyclodiode laser devices and their mechanism of action in glaucoma.</p></list-item><list-item><p>Identify&#x000a0;the indications for cyclodiode laser therapy.</p></list-item><list-item><p>Assess&#x000a0;the various surgical techniques available for cyclodiode treatment.</p></list-item><list-item><p>Communicate&#x000a0;the complications and risk factors for poor ocular outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140156&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140156">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140156.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Glaucoma represents a&#x000a0;spectrum of diseases that&#x000a0;culminates in a progressive optic neuropathy characterized by optic disc excavation, loss of the retinal ganglion cells,&#x000a0;and eventual visual field loss.<xref ref-type="bibr" rid="article-140156.r1">[1]</xref><xref ref-type="bibr" rid="article-140156.r2">[2]</xref> Intraocular pressure (IOP) is a&#x000a0;significant primary risk factor and is the only modifiable risk factor for which treatment can be directed to slow or halt progression.<xref ref-type="bibr" rid="article-140156.r3">[3]</xref>&#x000a0;In glaucomatous disease, the main treatment sites to lower IOP are targeted to improve the facility of aqueous outflow from the eye or reduce aqueous production at the ciliary processes.&#x000a0;</p>
        <p>Destruction of the ciliary body secretory epithelium to lower aqueous humor production and&#x000a0;treat refractory or uncontrolled glaucoma has been advocated since the early 1930s.<xref ref-type="bibr" rid="article-140156.r4">[4]</xref>&#x000a0;Cyclodestruction has been performed using various methods, including diathermy, surgical excision, cryotherapy, ultrasound, and laser. Cyclodiode laser has become the mainstay treatment of ciliary body destruction using an 810 nm&#x000a0;laser.<xref ref-type="bibr" rid="article-140156.r2">[2]</xref><xref ref-type="bibr" rid="article-140156.r5">[5]</xref>&#x000a0;Various subtypes of cyclodiode laser now exist, from Trans-scleral cyclophotocoagulation (TCP) to Micropulse (MP-TCP) and Endocyclophotocoagulation (ECP).<xref ref-type="bibr" rid="article-140156.r6">[6]</xref></p>
      </sec>
      <sec id="article-140156.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>Aqueous humor is produced from the ciliary processes. It predominantly drains via the pressure-dependent trabecular meshwork, with the residual component of aqueous humor draining via the pressure-independent uveal scleral pathway.</p>
        <p>There are approximately 80 ciliary processes, which are projections arising from the ciliary body, an encircling ring of smooth muscle lining the inner wall of the sclera. These ciliary processes consist of a double layer of epithelium protruding into the anterior chamber, overlying a core of stroma and fenestrated capillaries.&#x000a0;From the external surface of the eyeball, these ciliary processes are located approximately 1.5 mm posterior to the corneoscleral limbus.<xref ref-type="bibr" rid="article-140156.r7">[7]</xref><xref ref-type="bibr" rid="article-140156.r8">[8]</xref></p>
        <p>The continuous-wave TCP diode laser emits laser energy at a wavelength of 810 nm. When directed at the ciliary processes, it causes ablation of the ciliary epithelium, resulting in homogenous blanching and shrinking of the ciliary processes. Histopathologic studies have demonstrated significant damage to the pars plicata and surrounding tissues, including the sclera, pars plana, and iris root.&#x000a0;Adjacent damage to the pars plana provides another mechanism by which cyclodiode&#x000a0;acts by enhancing uveoscleral outflow.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref>&#x000a0;</p>
        <p>Unlike the continuous-wave TCP, MP-TCP delivers a series of short, pulsed repetitive bursts of laser energy in on/off phases, in which&#x000a0;the 'off-phase' allows time for surrounding tissues to cool, therefore lessening propagation of thermal damage while still lowering IOP.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref><xref ref-type="bibr" rid="article-140156.r9">[9]</xref>&#x000a0;In contrast to TCP, ECP laser&#x000a0;is performed under direct visualization of the ciliary processes, resulting in localized shrinkage of the ciliary processes and reduced thermal damage to surrounding tissues.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref><xref ref-type="bibr" rid="article-140156.r8">[8]</xref></p>
      </sec>
      <sec id="article-140156.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Cyclodiode laser&#x000a0;has traditionally been reserved for patients who have failed previous drainage surgery or suffer from refractory glaucomatous conditions, including neovascular, traumatic, aphakic, silicone-oil induced, inflammatory, and congenital/developmental glaucoma. Furthermore, blind, painful eyes or eyes with poor visual potential are also candidates. Cyclodiode laser is also recommended in eyes with significant conjunctival scarring from previous surgery, trauma, or inflammation.<xref ref-type="bibr" rid="article-140156.r2">[2]</xref><xref ref-type="bibr" rid="article-140156.r5">[5]</xref>&#x000a0; Cyclodiode has also been described in cases of acute angle-closure glaucoma unresponsive to conventional&#x000a0;medical and laser treatment. This allows the IOP to stabilize and inflammation to subdue before more definitive surgical procedures are undertaken.<xref ref-type="bibr" rid="article-140156.r10">[10]</xref></p>
        <p>Cyclodiode can also be utilized in non-surgical candidates and those who display poor compliance with treatment. Increasingly, cyclodiode is seen as a primary treatment option, even in eyes with good visual potential. This is particularly evident in developing countries as a viable long-term treatment option.<xref ref-type="bibr" rid="article-140156.r11">[11]</xref><xref ref-type="bibr" rid="article-140156.r12">[12]</xref><xref ref-type="bibr" rid="article-140156.r13">[13]</xref>&#x000a0;MP-TCP should be considered, especially in eyes at higher risk of postoperative complications, due to its more favorable safety profile.<xref ref-type="bibr" rid="article-140156.r9">[9]</xref>&#x000a0;ECP is commonly combined with cataract extraction but can equally be used as a primary intraocular procedure.<xref ref-type="bibr" rid="article-140156.r7">[7]</xref></p>
      </sec>
      <sec id="article-140156.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cyclodiode laser is generally not recommended in phthisical eyes with disorganized internal structures or where other alternative and more effective treatment modalities are available, especially in eyes with good vision or at risk of macular edema.<xref ref-type="bibr" rid="article-140156.r1">[1]</xref>&#x000a0;ECP is not recommended in patients with advanced pseudoexfoliation because the material obstructs energy uptake. Uveitic patients or neovascular glaucoma cases must also be considered carefully due to their risk of severe inflammation and hypotony post-operatively.<xref ref-type="bibr" rid="article-140156.r7">[7]</xref></p>
      </sec>
      <sec id="article-140156.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>The TCP unit is a portable compact device with a semiconductor solid-state diode laser system emitting energy at 810 nm. This device is connected to a&#x000a0;handpiece in the shape of a curved footplate, matching the spherical curvature of the sclera and enabling laser energy delivery.<xref ref-type="bibr" rid="article-140156.r14">[14]</xref><xref ref-type="bibr" rid="article-140156.r15">[15]</xref>&#x000a0;The laser energy is transmitted through a 600-um diameter quartz fiber oriented 1.2mm posterior to the limbus within the handpiece.&#x000a0;A tip protrudes 0.7mm beyond the probe to provide indentation on the ocular surface, thereby improving laser energy effectiveness. The continuous-wave laser energy is administered with the handpiece aligned&#x000a0;to the visual axis&#x000a0;on the conjunctiva surface for&#x000a0;the&#x000a0;duration of the desired burn.<xref ref-type="bibr" rid="article-140156.r15">[15]</xref><xref ref-type="bibr" rid="article-140156.r16">[16]</xref></p>
        <p>The MP-TCP is&#x000a0;also a portable device connected to a handpiece that similarly delivers laser energy to TCP in contact with the conjunctiva. Unlike the continuous-wave TCP, the MP-TCP&#x000a0;device is set on micropulse delivery with specific on-off times.<xref ref-type="bibr" rid="article-140156.r9">[9]</xref>&#x000a0;The ECP probe is inserted intraocularly on an 18-20G handpiece. It consists of an 810 nm diode laser, a 175 W xenon light source, a helium-neon laser aiming beam, and a video imaging camera. The endoscope provides a 110&#x000a0;to 160-degree field of view. This probe can be used in a pulsed or continuous-wave mode. ECP requires the addition of an operating microscope and the setup of an intraocular instrument.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref><xref ref-type="bibr" rid="article-140156.r7">[7]</xref><xref ref-type="bibr" rid="article-140156.r8">[8]</xref></p>
      </sec>
      <sec id="article-140156.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>This procedure is routinely performed in the operating theatres or dedicated minor operating rooms due to the hazards of laser scatter. The healthcare professionals undertaking this procedure include the primary ophthalmic surgeon with the assistance of a scrub nurse and/or theatre team. The ophthalmic surgeon may administer a peri/retrobulbar block, which may be performed by a supporting anesthetist if available.<xref ref-type="bibr" rid="article-140156.r17">[17]</xref></p>
      </sec>
      <sec id="article-140156.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>Appropriate patient selection and discussion regarding potential benefits, risks, recovery expectations, and complications are mandatory.&#x000a0;Similar to incisional&#x000a0;glaucoma procedures workups, the surgeon should consider the patient's general health, including the status of the other eye.&#x000a0;The patient&#x000a0;must&#x000a0;be assessed on their anesthetic suitability, whether they are a candidate for local anesthesia under peribulbar/retrobulbar block or whether they require a general anesthetic assessment.<xref ref-type="bibr" rid="article-140156.r16">[16]</xref>&#x000a0;If ECP is performed with combined cataract surgery, a complete ocular examination and subsequent biometry measurements for IOL selection are required.&#x000a0;</p>
        <p>This assessment should consider any concurrent ocular inflammation and preoperatively control this as necessary. It should also factor in any potential future interventional surgical operations the patient may later undertake and consider sparing the superotemporal quadrant of the conjunctiva if deemed a possibility.</p>
      </sec>
      <sec id="article-140156.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>During the laser procedure, all participants in the room must wear protective safety wear to avoid inadvertent laser scatter.&#x000a0;</p>
        <p>
<bold>TCP</bold>
</p>
        <p>If performed&#x000a0;under local anesthesia, a peribulbar block or retrobulbar block is administered preoperatively. The patient may also&#x000a0;receive sedation or, in rare cases, a general anesthetic.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref> The diode laser unit is calibrated to the user's desired settings, typically 1000&#x000a0;to 2000 mW for 1500&#x000a0;to 2000 ms duration.<xref ref-type="bibr" rid="article-140156.r17">[17]</xref>&#x000a0;The patient remains supine on the bed, and a speculum may be inserted to obtain adequate exposure to the eye.<xref ref-type="bibr" rid="article-140156.r4">[4]</xref></p>
        <p>It is recommended the ciliary body be identified with a handheld transilluminator before treatment to visualize the dark band of the ciliary processes, and this is particularly important in congenital cases where there may be distorted limbal anatomy.<xref ref-type="bibr" rid="article-140156.r15">[15]</xref><xref ref-type="bibr" rid="article-140156.r16">[16]</xref><xref ref-type="bibr" rid="article-140156.r17">[17]</xref>&#x000a0;Avoiding the 3 and 9 o'clock positions, representing the long ciliary artery and nerve, the handpiece is aligned with the heel of the footplate adjacent to the limbus, with the probe directed vertically in line with the visual axis.<xref ref-type="bibr" rid="article-140156.r4">[4]</xref><xref ref-type="bibr" rid="article-140156.r5">[5]</xref> The laser burns are applied around the limbus spaced half the width of the&#x000a0;handpiece apart from&#x000a0;1 other&#x000a0;by approximately 2 mm. This typically represents&#x000a0;6 burns per quadrant.<xref ref-type="bibr" rid="article-140156.r14">[14]</xref><xref ref-type="bibr" rid="article-140156.r18">[18]</xref></p>
        <p>The power is increased in increments from 150&#x000a0;to 250 mW/shot until an audible pop is heard, implying an excess of power resulting in an explosion of the ciliary processes and surrounding tissues. From here, the power level is titrated to just below the audible popping noise by similar increments. Depending on the desired IOP-lowering effect, 180&#x000a0;to 360 degrees can be administered to the&#x000a0;eye, ranging&#x000a0;from&#x000a0;12&#x000a0;to 40 spot burns.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref>&#x000a0;Postoperatively, topical corticosteroid drops are prescribed 4&#x000a0;to 8&#x000a0;times per day; depending on patient characteristics and clinician discretion, anti-ocular hypertensives are usually continued postoperatively initially and then tapered according to the postoperative IOP response.<xref ref-type="bibr" rid="article-140156.r11">[11]</xref><xref ref-type="bibr" rid="article-140156.r14">[14]</xref></p>
        <p>
<bold>MP-TCP</bold>
</p>
        <p>Similar to TCP, this procedure is generally performed under local anesthesia,&#x000a0;and the patient is positioned as per TCP. The MP-TCP device is set to pulse with specified on/off time frames, typically 0.5 ms 'on' and 1.1 ms 'off,' and its power ranges from 1600-2400 mW.</p>
        <p>A viscous coupling gel is applied to the eye to enable&#x000a0;sustained&#x000a0;contact of the probe with the ocular surface. The probe is placed adjacent to the limbus on the sclera, and the handpiece is aligned perpendicularly to the globe. The probe is then moved in a smooth, continuous back-and-forth painting motion with constant gentle pressure on the eye along the arc of the limbus, coursing over each quadrant or hemisphere. This technique similarly spares the 3 and 9 o'clock regions. Unlike TCP, no audible pop is heard to define an endpoint of maximal recommended power settings. Each quadrant receives 10&#x000a0;to 15 seconds of sweeping laser application and can undergo 3&#x000a0;to 5 repeat passes, with the total duration of laser application ranging from 80&#x000a0;to 360 seconds.&#x000a0;Postoperative drops are prescribed as per TCP.<xref ref-type="bibr" rid="article-140156.r9">[9]</xref><xref ref-type="bibr" rid="article-140156.r19">[19]</xref><xref ref-type="bibr" rid="article-140156.r20">[20]</xref></p>
        <p>
<bold>ECP</bold>
</p>
        <p>Preoperatively, dilating drops are applied to enhance pupillary dilatation for improved access and visualization of the ciliary processes. In rare cases, a peribulbar block is administered or performed under topical anesthetic with adjunct sedation or general anesthesia like TCP and MP-TCP. ECP is commonly performed during cataract surgery, post crystalline lens removal, and following IOL insertion to avoid inadvertent lens damage and enable deepening of the ciliary sulcus to facilitate further visualization and access.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref><xref ref-type="bibr" rid="article-140156.r7">[7]</xref><xref ref-type="bibr" rid="article-140156.r8">[8]</xref>&#x000a0;ECP is commonly performed via a limbal approach, with a 2.2&#x000a0;to 3.2 mm temporally-based corneal incision. A viscoelastic agent is then inserted into the anterior chamber and the ciliary sulcus to maintain anterior chamber stability and enlarge the space between the lens and the posterior surface of the iris.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref><xref ref-type="bibr" rid="article-140156.r7">[7]</xref><xref ref-type="bibr" rid="article-140156.r8">[8]</xref>&#x000a0;The endoscope probe is then inserted, and the video monitor view is orientated correctly; the probe is directed towards the ciliary sulcus to view the ciliary processes.</p>
        <p>The laser energy can be applied in a painting, sweeping fashion, or individually via direct shots upon visualization of the ciliary processes. It is recommended that up to 6 ciliary processes be in view to ascertain the correct working distance for effective laser application.<xref ref-type="bibr" rid="article-140156.r8">[8]</xref> Starting power parameters range from 200&#x000a0;to 300m W, and this is titrated as necessary to produce a whitening effect and shrinkage of the ciliary processes without tissue explosion. Up to 270 degrees of ciliary body can be treated with 1 corneal incision. However, 360-degree treatment requires an extra nasal or superior corneal incision.&#x000a0;</p>
        <p>Viscoelastic is removed from the anterior chamber via irrigation and aspiration, and the corneal wounds are sealed. Intracameral or subconjunctival antibiotics and corticosteroids are routinely given at the end of the procedure, followed by topical postoperative steroids and antibiotics.<xref ref-type="bibr" rid="article-140156.r7">[7]</xref><xref ref-type="bibr" rid="article-140156.r8">[8]</xref></p>
      </sec>
      <sec id="article-140156.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Complications following diode laser treatment vary depending on the type of diode laser employed, the underlying glaucomatous diagnosis, and the treatment protocol administered.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref>&#x000a0;Commonly observed complications following diode laser include transient mild-moderate discomfort, conjunctival hyperemia, conjunctival burns, conjunctival hyperpigmentation, transient pupillary ovalization, and transient anterior chamber inflammation. More serious reported complications include hyphaema, vitreous hemorrhage, loss of visual acuity, cataract formation, lens subluxation, malignant glaucoma, choroidal hemorrhage, scleral perforation, hypotony, phthisis bulbi, and sympathetic ophthalmia.<xref ref-type="bibr" rid="article-140156.r21">[21]</xref></p>
        <p>Energy levels in TCP&#x000a0;greater than 60J per treatment session are generally found to be at higher&#x000a0;risk of developing postoperative hypotony. Similarly, the greater number of shots delivered in TCP is a significant risk factor for hypotony.<xref ref-type="bibr" rid="article-140156.r14">[14]</xref><xref ref-type="bibr" rid="article-140156.r21">[21]</xref>&#x000a0;Other ocular risk factors&#x000a0;associated with higher rates of hypotony include neovascular glaucoma and a higher pre-treatment IOP. Sympathetic ophthalmia is an infrequent complication from TCP, and the exact rate of occurrence is estimated to range from 0.03 TO 0.17%.<xref ref-type="bibr" rid="article-140156.r21">[21]</xref></p>
        <p>MP-TCP is noted to have an improved safety profile compared to traditional TCP regarding rates of hypotony and phthisis bulbi, presumably due to its improved control in reducing collateral thermal tissue damage. Longer treatment duration and higher power settings are associated with higher rates of complications.<xref ref-type="bibr" rid="article-140156.r19">[19]</xref><xref ref-type="bibr" rid="article-140156.r20">[20]</xref><xref ref-type="bibr" rid="article-140156.r22">[22]</xref></p>
        <p>Potential risks from ECP include all of the above for&#x000a0;transscleral cyclodiode&#x000a0;except for conjunctival surface burns. Most studies suggest a lower rate of severe postoperative complications than TCP, particularly when power levels less than 500mW are applied.<xref ref-type="bibr" rid="article-140156.r8">[8]</xref><xref ref-type="bibr" rid="article-140156.r9">[9]</xref>&#x000a0;Given the intraocular nature of this procedure, other risks are present, including damage to the crystalline lens, zonular damage, iris damage, retinal detachment, and endophthalmitis.&#x000a0;To date, no cases of sympathetic ophthalmia have been reported from ECP.<xref ref-type="bibr" rid="article-140156.r5">[5]</xref></p>
      </sec>
      <sec id="article-140156.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Although the definitions of success vary, multiple long-term follow-up studies report TCP as having an effective IOP reduction in 34&#x000a0;to 94% of cases&#x000a0;with a mean follow-up of 2&#x000a0;to 5 years.&#x000a0;Hypotony is reported in up to 10% of cases, phthisical development in up to 5% of cases, and vision loss is reported in up to 28% of cases.<xref ref-type="bibr" rid="article-140156.r14">[14]</xref><xref ref-type="bibr" rid="article-140156.r16">[16]</xref><xref ref-type="bibr" rid="article-140156.r23">[23]</xref>&#x000a0;Rotchford et al. described refractory and non-refractory glaucoma, and those with good vision were treated with TCP. They reported an&#x000a0;effective&#x000a0;IOP reduction in 79.6%, with no cases of hypotony and median visual acuity loss of 2 lines or more in 30.6%, which was similar to the proportion of vision loss associated following trabeculectomy surgery and was predominantly attributed to glaucomatous progression rather than macular edema.<xref ref-type="bibr" rid="article-140156.r13">[13]</xref>&#x000a0;</p>
        <p>More standardized protocols of lower energy delivery display&#x000a0;lower rates of serious complications compared to initial studies. Notably, this treatment can assist in reducing the medical burden of anti-ocular hypertensive treatment on patients, particularly&#x000a0;in the cessation of oral acetazolamide.<xref ref-type="bibr" rid="article-140156.r11">[11]</xref><xref ref-type="bibr" rid="article-140156.r14">[14]</xref></p>
        <p>Various studies reviewing&#x000a0;MP-TCP have reported a 52% and 74% success rate with a final IOP of less than 21 mmHg or a 20% reduction in IOP. Hypotony has been reported in 5&#x000a0;to 18% of cases, with vision loss of 2 lines or more occurring in 9-19% of cases. Of note, the higher documented complication rates were associated with longer treatment duration. MP-TCP has been documented to lower IOP and reduce treatment medication burden effectively but with lower rates of significant complications compared to TCP.<xref ref-type="bibr" rid="article-140156.r20">[20]</xref><xref ref-type="bibr" rid="article-140156.r22">[22]</xref><xref ref-type="bibr" rid="article-140156.r24">[24]</xref></p>
        <p>Multiple comparative trials reviewing ECP in cases of adult refractory glaucoma describe a success rate between 74 and 90% with a final IOP of 21 mmHg or less. Hyptony has been reported in up to 8% of cases, phthisis bulbi in 3% of cases, and vision loss in up to 6% of cases.<xref ref-type="bibr" rid="article-140156.r8">[8]</xref>&#x000a0; ECP appears to be an emerging treatment modality, with initial studies documenting its success in refractory glaucoma.<xref ref-type="bibr" rid="article-140156.r25">[25]</xref>&#x000a0;Recent studies have shown ECP &#x000a0;to be comparable to Ahmed drainage devices following previous failed tube surgery.<xref ref-type="bibr" rid="article-140156.r26">[26]</xref>&#x000a0;ECP can be combined with cataract surgery and other accessory outflow procedures to enhance IOP-lowering effects. Cyclodiode laser is an emerging and growing treatment for managing glaucoma that is not solely relegated to&#x000a0;refractory cases. The expansion of diode laser delivery devices has further led to the development and refinement of cyclodiode laser as a primary procedure in the developing world, even in eyes with less advanced glaucoma and good visual potential.<xref ref-type="bibr" rid="article-140156.r27">[27]</xref><xref ref-type="bibr" rid="article-140156.r28">[28]</xref></p>
      </sec>
      <sec id="article-140156.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cyclodiode is an evolving treatment for glaucomatous disease, not solely resigned to managing refractory cases. A thorough preoperative workup and assessment must ensure patient suitability and attain satisfactory IOP reduction while minimizing potential postoperative complications. The patient consents to and is made aware of other treatment modalities that can be considered.</p>
        <p>On the day of surgery, the interprofessional team consists of an ophthalmic surgeon, ophthalmic nurses, and operating room staff. The team must ensure consent is obtained and the eyes for surgery are appropriately marked. Local laser safety protocols and procedures must be followed during the procedure. The nursing staff postoperatively ensures the patient's prescription is available, informs them of the drop regime, educates them&#x000a0;on potential symptoms and complications, and arranges&#x000a0;further follow-up in the eye clinic.</p>
      </sec>
      <sec id="article-140156.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140156&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140156">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140156/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140156">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-140156.s14">
        <title>References</title>
        <ref id="article-140156.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pastor</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Juzych</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Netland</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>NT</given-names>
              </name>
            </person-group>
            <article-title>Cyclophotocoagulation: a report by the American Academy of Ophthalmology.</article-title>
            <source>Ophthalmology</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>108</volume>
            <issue>11</issue>
            <fpage>2130</fpage>
            <page-range>2130-8</page-range>
            <pub-id pub-id-type="pmid">11713091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of glaucoma: a review.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2012</year>
            <season>May-Jun</season>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>388</fpage>
            <page-range>388-99</page-range>
            <pub-id pub-id-type="pmid">22339885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anand</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Klug</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nirappel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sol&#x000e1;-Del Valle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A Review of Cyclodestructive Procedures for the Treatment of Glaucoma.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>17</day>
            <volume>35</volume>
            <issue>5-6</issue>
            <fpage>261</fpage>
            <page-range>261-275</page-range>
            <pub-id pub-id-type="pmid">32936725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>JJC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>KKW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SWK</given-names>
              </name>
            </person-group>
            <article-title>Retrospective review on the outcome and safety of transscleral diode laser cyclophotocoagulation in refractory glaucoma in Chinese patients.</article-title>
            <source>Int Ophthalmol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-46</page-range>
            <pub-id pub-id-type="pmid">29230617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2008</year>
            <season>Apr-May</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-47</page-range>
            <pub-id pub-id-type="pmid">18414112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>What's new in laser treatment for glaucoma?</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-7</page-range>
            <pub-id pub-id-type="pmid">22186007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fellman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Noecker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Samuelson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uram</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jampel</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic ophthalmic surgery of the anterior segment.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2014</year>
            <season>Mar-Apr</season>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-31</page-range>
            <pub-id pub-id-type="pmid">23931901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic cyclophotocoagulation for the treatment of glaucoma.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2017</year>
            <season>May-Jun</season>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-365</page-range>
            <pub-id pub-id-type="pmid">27717892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>SWY</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JKW</given-names>
              </name>
            </person-group>
            <article-title>Micropulse laser for the treatment of glaucoma: A literature review.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2019</year>
            <season>Jul-Aug</season>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>486</fpage>
            <page-range>486-497</page-range>
            <pub-id pub-id-type="pmid">30639207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Cyclodiode laser in the treatment of acute angle closure.</article-title>
            <source>Eye (Lond)</source>
            <year>2012</year>
            <month>May</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>742</fpage>
            <page-range>742-5</page-range>
            <pub-id pub-id-type="pmid">22302062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gandhewar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma.</article-title>
            <source>Eye (Lond)</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>936</fpage>
            <page-range>936-40</page-range>
            <pub-id pub-id-type="pmid">16628239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egbert</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Fiadoyor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Budenz</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Dadzie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>345</fpage>
            <page-range>345-50</page-range>
            <pub-id pub-id-type="pmid">11231767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rotchford</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Jayasawal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Madhusudhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Transscleral diode laser cycloablation in patients with good vision.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>9</issue>
            <fpage>1180</fpage>
            <page-range>1180-3</page-range>
            <pub-id pub-id-type="pmid">20576775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vernon</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Koppens</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Negi</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Diode laser cycloablation in adult glaucoma: long-term results of a standard protocol and review of current literature.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-20</page-range>
            <pub-id pub-id-type="pmid">16872335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dulku</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The UK National Cyclodiode Laser Survey.</article-title>
            <source>Eye (Lond)</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>168</fpage>
            <page-range>168-73</page-range>
            <pub-id pub-id-type="pmid">21127509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spencer</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>"Cyclodiode": results of a standard protocol.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-6</page-range>
            <pub-id pub-id-type="pmid">10365039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloom</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Hitchings</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Khaw</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>"Cyclodiode". Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma.</article-title>
            <source>Ophthalmology</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>104</volume>
            <issue>9</issue>
            <fpage>1508</fpage>
            <page-range>1508-19; discussion 1519-20</page-range>
            <pub-id pub-id-type="pmid">9307649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosoko</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gaasterland</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Enger</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group.</article-title>
            <source>Ophthalmology</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>103</volume>
            <issue>8</issue>
            <fpage>1294</fpage>
            <page-range>1294-302</page-range>
            <pub-id pub-id-type="pmid">8764801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Yelenskiy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McKnight</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>JCH</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Micropulse Transscleral Diode Laser Cyclophotocoagulation in Refractory Glaucoma: Short-Term Efficacy, Safety, and Impact of Surgical History on Outcomes.</article-title>
            <source>Ophthalmol Glaucoma</source>
            <year>2019</year>
            <season>Nov-Dec</season>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>402</fpage>
            <page-range>402-412</page-range>
            <pub-id pub-id-type="pmid">32672572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chockalingam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aquino</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ZI</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-72</page-range>
            <pub-id pub-id-type="pmid">20447122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aujla</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Incidence of hypotony and sympathetic ophthalmia following trans-scleral cyclophotocoagulation for glaucoma and a report of risk factors.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>761</fpage>
            <page-range>761-72</page-range>
            <pub-id pub-id-type="pmid">23433313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aquino</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Loon</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2015</year>
            <season>Jan-Feb</season>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">24811050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walland</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Diode laser cyclophotocoagulation: longer term follow up of a standardized treatment protocol.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>263</fpage>
            <page-range>263-7</page-range>
            <pub-id pub-id-type="pmid">11021554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelrahman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>El Sayed</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Micropulse Versus Continuous Wave Transscleral Cyclophotocoagulation in Refractory Pediatric Glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>900</fpage>
            <page-range>900-905</page-range>
            <pub-id pub-id-type="pmid">30113515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Alvarado</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic photocoagulation of the ciliary body for treatment of refractory glaucomas.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>124</volume>
            <issue>6</issue>
            <fpage>787</fpage>
            <page-range>787-96</page-range>
            <pub-id pub-id-type="pmid">9402825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murakami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akil</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chahal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dustin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic cyclophotocoagulation versus second glaucoma drainage device after prior aqueous tube shunt surgery.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-246</page-range>
            <pub-id pub-id-type="pmid">27570215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Madike</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Selva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Casson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>CX</given-names>
              </name>
            </person-group>
            <article-title>Changing trends in glaucoma surgery within Australia.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>106</volume>
            <issue>7</issue>
            <fpage>957</fpage>
            <page-range>957-961</page-range>
            <pub-id pub-id-type="pmid">33597199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140156.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conlon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saheb</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>II</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma treatment trends: a review.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>114</fpage>
            <page-range>114-124</page-range>
            <pub-id pub-id-type="pmid">28237137</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
